Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KRT009
MIFTS: 53

Keratosis

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Keratosis

About this section

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 43 15 17 71
Actinic Keratosis 71
Hyperkeratosis 71

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:161
MeSH 43 D007642
NCIt 49 C34747
UMLS 71 C0022593 C0022602 C0870082
Sources

Summaries for Keratosis

About this section
Disease Ontology : 12 A skin disease characterized by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis, seborrheic and keratosis follicularis spinulosa decalvans, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is MBTPS2 (Membrane Bound Transcription Factor Peptidase, Site 2), and among its related pathways/superpathways are Developmental Biology and Shigellosis. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and testes, and related phenotypes are Increased vaccinia virus (VACV) infection and cellular

Wikipedia : 74 Keratosis (from kerat- + -osis) is a growth of keratin on the skin or on mucous membranes stemming from... more...

Sources

Related Diseases for Keratosis

About this section

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 keratosis, seborrheic 34.8 TP53 PIK3CA KRT10 FGFR3
2 keratosis follicularis spinulosa decalvans 34.7 SAT1 MBTPS2 LRP1
3 erythrokeratodermia variabilis et progressiva 1 33.5 KRT1 GJB2 GJA1
4 palmoplantar keratoderma, epidermolytic 33.2 KRT9 KRT10 KRT1 FLG DSG1 CTSC
5 ichthyosis vulgaris 33.2 KRT10 KRT1 FLG
6 clear cell acanthoma 33.0 KRT10 FLG
7 hereditary palmoplantar keratoderma 32.8 KRT9 DSG1
8 focal palmoplantar keratoderma 32.7 GJB2 DSG1
9 striate palmoplantar keratoderma 32.7 SERPINB7 KRT10 KRT1 DSP DSG1 CTSC
10 palmoplantar keratosis 32.7 SLURP1 SERPINB7 MBTPS2 KRT9 KRT10 KRT1
11 diffuse palmoplantar keratoderma 32.5 KRT9 KRT1 DSP DSG1
12 acrokeratosis verruciformis 32.2 KRT1 ATP2A2
13 dermatosis papulosa nigra 32.0 PIK3CA FGFR3
14 lichen planus 31.3 TP53 KRT10 KRT1 FLG DSG1
15 papilloma 31.1 TP53 KRT10 KRT1 FLG FGFR3
16 skin atrophy 31.0 MBTPS2 GJA1 FLG
17 keratoacanthoma 31.0 TP53 KRT10 FLG DSG1
18 porokeratosis 31.0 TP53 KRT1 FLG FGFR3
19 eccrine acrospiroma 31.0 TP53 KRT10
20 benign chronic pemphigus 30.8 DSP DSG1 ATP2A2
21 discoid lupus erythematosus 30.8 KRT10 FLG
22 epidermolytic hyperkeratosis 30.6 KRT9 KRT10 KRT1 FLG
23 large cell acanthoma 30.6 TP53 KRT10
24 ichthyosis 30.5 POMP MBTPS2 KRT10 KRT1 GJB2 GJA1
25 hypotrichosis 30.5 MBTPS2 GJB2 GJA1 FLG DSG1 CTSC
26 epidermolysis bullosa 30.4 KRT10 KRT1 FLG DSP
27 pseudoainhum 30.3 GJB2 GJA1
28 skin squamous cell carcinoma 30.2 TP53 KRT10 KRT1
29 knuckle pads, leukonychia, and sensorineural deafness 30.2 GJB2 GJA1
30 nevus, epidermal 30.2 PIK3CA KRT10 KRT1 GJB2 FGFR3
31 obsolete: squamous cell carcinoma of head and neck 30.0 TP53 PIK3CA FGFR3
32 knuckle pads 30.0 KRT9 GJB2 GJA1
33 acantholytic acanthoma 30.0 DSG1 ATP2A2
34 skin disease 29.8 SLURP1 KRT9 KRT10 KRT1 GJB2 GJA1
35 pachyonychia congenita 1 29.6 MBTPS2 KRT9 KRT10 KRT1 FLG DSP
36 actinic keratosis 12.8
37 keratosis pilaris atrophicans 12.6
38 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 12.6
39 keratosis follicularis spinulosa decalvans, x-linked 12.6
40 keratosis follicularis, dwarfism, and cerebral atrophy 12.5
41 keratosis, focal palmoplantar and gingival 12.5
42 keratosis follicularis spinulosa decalvans, autosomal dominant 12.5
43 inverted follicular keratosis 12.4
44 vulvar inverted follicular keratosis 12.3
45 vulvar seborrheic keratosis 12.3
46 inflamed seborrheic keratosis 12.3
47 keratosis palmoplantaris striata iii 12.3
48 keratosis palmaris et plantaris with clinodactyly 12.3
49 darier-white disease 12.3
50 keratosis palmoplantaris striata ii 12.2

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis
Sources

Symptoms & Phenotypes for Keratosis

About this section

UMLS symptoms related to Keratosis:


pruritus, exanthema, trichorrhexis invaginata

GenomeRNAi Phenotypes related to Keratosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased vaccinia virus (VACV) infection GR00249-S 9.62 AAGAB ATP2A2 CTSC DSG1 DSP FGFR3

MGI Mouse Phenotypes related to Keratosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
2 growth/size/body region MP:0005378 9.97 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1
3 integument MP:0010771 9.73 ATP2A2 CTSC DSG1 DSP FGFR3 GJA1
4 skeleton MP:0005390 9.28 ATP2A2 DSG1 FGFR3 GJA1 GJB2 LRP1
Sources

Drugs & Therapeutics for Keratosis

About this section

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
7
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
8
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Prilocaine Approved Phase 4 721-50-6 4906
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
carbamide peroxide Approved Phase 4 124-43-6
13
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
14
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
15
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
16
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
17
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
18
Aminolevulinic acid Approved Phase 4 106-60-5 137
19
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
23
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
24
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
25
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
28
Protoporphyrin IX Experimental Phase 4 553-12-8
29 Sunscreening Agents Phase 4
30 Vitamin B3 Phase 4
31 Vitamin B Complex Phase 4
32 Vitamin B9 Phase 4
33 Folate Phase 4
34 Nicotinic Acids Phase 4
35 Hypoglycemic Agents Phase 4
36 Immunosuppressive Agents Phase 4
37 Trace Elements Phase 4
38 Hormones Phase 4
39 Micronutrients Phase 4
40 Nutrients Phase 4
41 Vitamins Phase 4
42 Calcium, Dietary Phase 4
43 Cyclooxygenase Inhibitors Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 retinol Phase 4
46 Retinol palmitate Phase 4
47 Polymyxins Phase 4
48 Lidocaine, Prilocaine Drug Combination Phase 4
49 Anesthetics, Local Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 355)
# Name Status NCT ID Phase Drugs
1 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
2 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
3 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
4 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Unknown status NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
7 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
8 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
9 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
10 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
11 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
12 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
13 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
14 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
16 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
17 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
18 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
19 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
20 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
21 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
22 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
23 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
24 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
25 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
26 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
27 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
28 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
29 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
30 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
31 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
32 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
33 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
34 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
35 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
36 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
37 Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment Completed NCT01703325 Phase 4 0.1% triamcinolone , 0.05% clobetasol propionate ointment
38 The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study Completed NCT03212625 Phase 4 Urea Cream 20%;Placebos
39 Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial Completed NCT00599807 Phase 4
40 Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome. Completed NCT02097615 Phase 4
41 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
42 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
43 Standard Management and Chlorhexidine Gluconate Solution at 0.125% Versus Standard Management and Physiological Saline Sterile Solution for Healing Grade IIB Ulcers in Diabetic Foot Syndrome: Clinical Trial Recruiting NCT03209466 Phase 4 Chlorhexidine gluconate at 0.125%;Placebo Comparator with physiological saline sterile solution
44 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
45 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Not yet recruiting NCT03963102 Phase 4 Ameluz
46 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
47 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
48 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
49 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
50 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Fluorouracil
Masoprocol

Cochrane evidence based reviews: keratosis

Sources

Genetic Tests for Keratosis

About this section
Sources

Anatomical Context for Keratosis

About this section

MalaCards organs/tissues related to Keratosis:

40
Skin, Breast, Testes, T Cells, Tongue, Lung, Kidney
Sources

Publications for Keratosis

About this section

Articles related to Keratosis:

(show top 50) (show all 9880)
# Title Authors PMID Year
1
Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. 61
31589773 2020
2
Iceberg sign in actinic keratosis neglecta caused by toning shampoo for blonde and white hair. 61
31724156 2020
3
Reducing unpleasant side effects of topical 5-Fluorouracil treatment for actinic keratosis: a randomized controlled trial. 61
30821548 2020
4
Basaloid tumors arising from seborrheic keratosis: Malignant basal cell carcinoma or benign basaloid follicular hamartomatous proliferation? 61
31682281 2020
5
The different faces of mycosis fungoides: results of a single-center study. 61
31782525 2020
6
[Staphylococcal scalded skin syndrome in a pediatric patient with atopic dermatitis]. 61
31984705 2020
7
Association between teat-end hyperkeratosis and mastitis in dairy cows: A systematic review. 61
31759610 2020
8
Photodynamic Therapy for Photodamage, Actinic Keratosis, and Acne in the Cosmetic Practice. 61
31779937 2020
9
Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016. 61
31673980 2020
10
Assessment of Clinical and Histological Changes in the Skin Paddle of Pectoralis Major Myocutaneous Flap in Intraoral Reconstruction: A Prospective Cohort Study. 61
31633547 2020
11
Current therapies for actinic keratosis. 61
32012240 2020
12
Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a systematic review and meta-analysis. 61
31928689 2020
13
Influence of Serum Vitamin D Level in the Response of Actinic Keratosis to Photodynamic Therapy with Methylaminolevulinate. 61
32024208 2020
14
Photodynamic therapy for the prevention and treatment of actinic keratosis/squamous cell carcinoma in solid organ transplant recipients: a systematic review and meta-analysis. 61
31394005 2020
15
[Current indications for plasma therapy in dermatology]. 61
31965204 2020
16
A feasibility study of microwave therapy for precancerous actinic keratoses. 61
32030723 2020
17
Lichen planopilaris and dyslipidemia: systematic review and meta-analysis. 61
32030783 2020
18
A broad range of symptoms in allgrove syndrome: single center experience in Southeast Anatolia. 61
31435881 2020
19
Onychomatricoma Micropapilliferum, a New Variant of Onychomatricoma: Clinical, Dermoscopical, and Histological Correlations (Report of 4 Cases). 61
31436573 2020
20
p53-Regulated Long Noncoding RNA PRECSIT Promotes Progression of Cutaneous Squamous Cell Carcinoma via STAT3 Signaling. 61
31837949 2020
21
Size of supernumerary teats in sheep correlates with complexity of the anatomy and microenvironment. 61
31898326 2020
22
Value of pre- and intraoperative diagnostic methods in suspected glottic neoplasia. 61
31654182 2020
23
Knockdown of sodium channel Nax reduces dermatitis symptoms in rabbit skin. 61
31925326 2020
24
Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome. 61
31895414 2020
25
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. 61
31895432 2020
26
"Comparative study between the efficacy of fractional CO2 laser, Q-switched Nd:YAG laser (1064 nm), and both types in treatment of keratosis pilaris". 61
31927647 2020
27
NUAK2 localization in normal skin and its expression in a variety of skin tumors with YAP. 61
32001115 2020
28
Topical and device-based treatments for fungal infections of the toenails. 61
31978269 2020
29
[Lymphedema-clinical picture and therapy]. 61
31912161 2020
30
Oral Verruciform Xanthoma: A Series of 212 Cases and Review of the Literature. 61
31898056 2020
31
Erosive pustular dermatosis of the scalp: a multicentre study. 61
31954062 2020
32
Dermatologic Problems Commonly Seen by the Allergist/Immunologist. 61
31351991 2020
33
Follicular occlusion disorders in Down syndrome patients. 61
31626333 2020
34
HPV-positive Squamous Cell Carcinoma of the Larynx, Oral Cavity, and Hypopharynx: Clinicopathologic Characterization With Recognition of a Novel Warty Variant. 61
31934915 2020
35
Poxviruses diagnosed in cattle from Distrito Federal, Brazil (2015-2018). 61
31971341 2020
36
A Step Toward Standardizing Clinical Trials of Actinic Keratosis. 61
31939998 2020
37
Core Outcome Set for Actinic Keratosis Clinical Trials. 61
31939999 2020
38
Keratosis obturans complicated with facial nerve palsy: a diagnostic dilemma. 61
27269254 2020
39
TERT promoter mutations in actinic keratosis before and after treatment. 61
31970758 2020
40
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. 61
31407414 2020
41
Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen's Disease, and Cutaneous Squamous Cell Carcinoma. 61
31254517 2020
42
The conventional protocol vs. a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. 61
31021404 2020
43
Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomised intra-individual study. 61
31955461 2020
44
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs imiquimod vs ingenol mebutate vs methylaminolevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. 61
31961446 2020
45
[Interdisciplinary Management of Tumours of the Eyelid and Periorbital Region]. 61
31968366 2020
46
Psoriatic Nails; Severe Dystrophy and Hyperkeratosis. 61
31977654 2020
47
Multiple minute digitate hyperkeratosis, familial type: A rare entity. 61
31793494 2020
48
5-aminolevulinic acid patch (Alacare) PDT for actinic cheilitis: data from a prospective 12-month follow-up study on 21 patients. 61
31999856 2020
49
Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma. 61
31944277 2020
50
Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-Clinical review and future perspectives. 61
31923431 2020
Sources

Variations for Keratosis

About this section
Sources

Expression for Keratosis

About this section
Search GEO for disease gene expression data for Keratosis.
Sources

Pathways for Keratosis

About this section

Pathways related to Keratosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Developmental Biology 65
Show member pathways
 12.97 PIK3CA KRT9 KRT10 KRT1 FLG FGFR3
2
Shigellosis 36
12.04 TP53 PIK3CA GJB2 GJA1
3
Staphylococcus aureus infection 36
11.56 KRT9 KRT10 DSG1
4
Keratinization 65
Show member pathways
 11.56 KRT9 KRT10 KRT1 FLG DSP DSG1
5
Central carbon metabolism in cancer 36
11.27 TP53 PIK3CA FGFR3
6
Antiarrhythmic Pathway, Pharmacodynamics 60
10.88 GJA1 DSP ATP2A2
7
Oligomerization of connexins into connexons 65
Show member pathways
 10.28 GJB2 GJA1
Sources

GO Terms for Keratosis

About this section

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.2 TP53 POMP PIK3CA MBTPS2 LRP1 KRT9
2 cytoplasm GO:0005737 10.1 TP53 SERPINB7 SAT1 POMP PIK3CA MBTPS2
3 intermediate filament GO:0005882 9.35 KRT9 KRT10 KRT1 FLG DSP
4 fascia adherens GO:0005916 9.16 GJA1 DSP
5 cornified envelope GO:0001533 9.02 KRT10 KRT1 FLG DSP DSG1

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.69 KRT9 DSP ATP2A2
2 keratinocyte differentiation GO:0030216 9.61 KRT10 FLG DSP
3 response to ischemia GO:0002931 9.58 TP53 GJB2 GJA1
4 keratinization GO:0031424 9.55 KRT9 KRT10 KRT1 DSP DSG1
5 response to retinoic acid GO:0032526 9.54 TP53 GJB2 GJA1
6 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.49 TP53 MBTPS2
7 gap junction assembly GO:0016264 9.48 GJB2 GJA1
8 cell communication by electrical coupling GO:0010644 9.46 GJB2 GJA1
9 epididymis development GO:1905867 9.32 GJB2 GJA1
10 bone maturation GO:0070977 9.26 MBTPS2 FGFR3
11 peptide cross-linking GO:0018149 9.26 KRT10 KRT1 FLG DSP
12 cornification GO:0070268 9.1 KRT9 KRT10 KRT1 FLG DSP DSG1

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.19 TP53 SLURP1 SAT1 POMP PIK3CA MBTPS2
2 gap junction channel activity GO:0005243 9.16 GJB2 GJA1
3 gap junction channel activity involved in cell communication by electrical coupling GO:1903763 8.96 GJB2 GJA1
4 structural constituent of epidermis GO:0030280 8.8 KRT10 KRT1 FLG
Sources

Sources for Keratosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....